Clinical pharmacodynamic factors in docetaxel toxicity

British Journal of Cancer

Volumn 97, Issue 3, 2007, Pages 290-296

  Puisset, F ^a   Alexandre, J ^b   Treluyer, J M ^b   Raoul, V ^a   Roche H ^a   Goldwasser, F ^b   Chatelut, E ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Docetaxel; Individual dosing; Pharmacodynamics; Pharmacokinetics; Population analysis

Indexed keywords

DEXAMETHASONE; DOCETAXEL; OROSOMUCOID;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; NEUTROPHIL; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; MALE; MIDDLE AGED; TAXOIDS;

EID: 34547584175     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603872     Document Type: Article

References (12)

1. Baille P, Bruno R, Schellens JH, Webster LK, Millward M, Verweij J, Montay G (1997) Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 3: 1535-1538
2. Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A (2005) Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 77: 43-53
3. Baker SD, Sparreboom A, Verweij J (2006) Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 45: 235-252
4. Beal SL, Sheiner LB (1982) Estimating population kinetics. Crit Rev Biomed Eng 8: 195-222
5. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24: 153-172
6. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20: 4713-4721
7. Minami H, Ohe Y, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y, Nokihara H, Sekine I, Saijo N, Hanada K, Ogata H (2004) Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J Clin Oncol 22: 2901-2908
8. Puisset F, Chatelut E, Dalenc F, Busi F, Cresteil T, Azema J, Poublanc M, Hennebelle I, Lafont T, Chevreau C, Roche H (2004) Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 54: 265-272
9. Puisset F, Chatelut E, Sparreboom A, Delord JP, Berchery D, Lochon I, Lafont T, Roche H (2007) Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemother Pharmacol 60: 305-308
10. ten Tije AJ, Verweij J, Carducci MA, Graveland W, Rogers T, Pronk T, Verbruggen MP, Dawkins F, Baker SD (2005) Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23: 1070-1077
11. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Treluyer JM (2006) Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79: 570-580
12. Urien S, Barre J, Morin C, Paccaly A, Montay G, Tillement JP (1996) Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 14: 147-151